BEY-1107 is under clinical development by BeyondBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BEY-1107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BEY-A is under development for the treatment of metastatic colorectal cancer, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma and recurrent glioblastoma multiforme. The drug candidate is administered by the oral route. It acts by targeting CDK1.
For a complete picture of BEY-1107’s drug-specific PTSR and LoA scores, buy the report here.